Additional InformationTHE PHARMACEUTICAL MARKET: GREECE - REVIEW
According to the EIU, Greece faces another year of negative growth in 2012, following three years of economic decline and plunging living standards. The economy should flatten out during 2013 and then grow modestly between 2014 and 2016. This forecast assumes that a large write-down of debt and continued government commitment to austerity make the public finances a little more manageable and that Greece remains in the euro zone. An exit from the euro zone involving redenomination of salaries and bank deposits in a depreciating currency would lead to an even more severe decline in living standards than currently expected.
The macroenvironment for the Greek pharmaceutical industry remains challenging. Politically, an election is likely to take place in mid-April. Economically, in addition to the huge budget deficit, recession in Greece is still ongoing. Legally, Greece remained on the USTR’s Watch List in 2011 due to concerns over IPR enforcement. Demographically, Greece has an ageing population, and latest projections expect that the population aged 65 and over will constitute approximately one-fifth of the total population by 2016. As a result, healthcare is increasingly focused on preventative care and there will be a continuing demand for new therapies so that patients can be treated more effectively.
In June 2011, it was reported that Roche stopped delivering medicines to Greek public hospitals that had not paid outstanding invoices since 1st September 2010. The Hellenic Association of Pharmaceutical Companies (SFEE) raised concerns about the money owed to its members. According to SFEE, public hospitals only paid for nearly two-fifths of the 1.9 billion euros (US$2.4 billion) worth of drugs delivered by SFEE member companies between January 2010 and June 2011.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
More Prescription Drugs reports by Espicom Healthcare Intelligence
Understanding the US's Regional Healthcare Markets by Espicom Healthcare Intelligence
Understanding the US's Regional Healthcare Markets
For years to come, the US healthcare market will remain the most attractive to providers of medical services. Considerable ...
The Pharmaceutical Market: Brazil by Espicom Healthcare Intelligence
The Pharmaceutical Market: Brazil
OVERVIEW OF THE PHARMACEUTICAL MARKET IN BRAZIL The Brazilian pharmaceutical market remains our favourite regional market in Latin America due to ...
Inhalation & Nasal Spray Generic Drugs 2013 by Espicom Healthcare Intelligence
Inhalation & Nasal Spray Generic Drugs 2013
Around three quarters of the US$36.4 billion respiratory prescription drugs market comprises drugs that are delivered using inhalation ...
See all reports like this >>
Middle East North Africa Pharmaceutical Market Forecasts to 2018 by Espicom Healthcare Intelligence
Middle East North Africa Pharmaceutical Market Forecasts to 2018
The global pharmaceutical market is forecast to be worth over US$1,250 billion by 2018 - but ...
More Greece Prescription Drugs reports
Pharmaceuticals and Healthcare Report Q3 2014 - Greece by Business Monitor International
Greece Pharmaceuticals and Healthcare Report Q3 2014BMI View: The Greek pharmaceutical and healthcare sector will continue contract over the medium-tolongterm. Although Greece's financial outlook has ...
Greece Pharmaceuticals and Healthcare Report Q2 2014 by Business Monitor International
Greece Pharmaceuticals and Healthcare Report Q2 2014BMI View: Despite the Greek economy's expected return to growth in 2014, we expect no lessening in thepressures on ...
Greece Pharmaceuticals and Healthcare Report Q1 2013 by Business Monitor International
BMI View: The Greek pharmaceutical market has been characterised of late by mandated price reductions,state intervention in the trade of pharmaceutical goods, regressive revenue taxes, ...
See all reports like this >>
Greece Pharmaceuticals and Healthcare Report Q4 2012 by Business Monitor International
BMI View: The immediate threat of a Greek default and eurozone exit was reduced as the outcome of thelegislative elections in June had a much ...
More Greece reports
D&B Country RiskLine Report: Greece by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
See all reports like this >>
D&B Country Report: Greece by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...